Navigation Links
Novo Nordisk Wins Design Award for NovoTwist(TM) Needle

COPENHAGEN, October 26 /PRNewswire/ -- Novo Nordisk has been awarded a Good Design Award(TM)(1) for NovoTwist(TM), the new needle designed for use with the insulin delivery device FlexPen(R). The needle, which has a simple 'just twist' attachment and detachment, makes injection easier for people with diabetes.

The Good Design Award(TM) (also known as G-Mark Award)(1) from the Japan Industrial Design Promotion Organization is a mark of true quality and gives recognition to the uniqueness of NovoTwist(TM). Nearly 3,000 entries were narrowed down by the judging panel and NovoTwist(TM) was selected for an award in the 'Society - Medical Equipment' section.(1) Previous winners of the Good Design Award(TM) include Apple, Toshiba, Toyota and Nintendo. The Good Design Award(TM)(1) highlights the unique design features of NovoTwist(TM). The judges specifically commented that "Conventional screw thread needles can be difficult to attach and detach, especially for the elderly, as limited manual dexterity and hand strength make the circular motion of screw attachment/detachment challenging. NovoTwist(TM) has solved this problem with a simple functional design with a push-and- twist needle attachment/detachment system."

When used with FlexPen(R), three out of four patients prefer NovoTwist(TM) to conventional needles,(2) and patients find NovoTwist(TM) easier to use, less timeconsuming and more user-friendly than conventional needles.(2,3) These benefits may be important to people with diabetes who seek easier and more discreet methods of self-administering insulin.

"Given the general anxiety that some people with diabetes can suffer when using any injection device, the new developments with NovoTwist(TM) are a big step forward in terms of user-friendliness," says diabetes nurse Barbel Sommavilla (Diabetes Education Center, Salzburg, Austria) who was involved in a key study assessing patients' preference for insulin pen needles. According to Sommavilla et al 2008, the needle is preferred by people with diabetes.(2)

Novo Nordisk has a long tradition of innovative design. In 2005, the insulin pen NovoPen(R)(4) was also given a Good Design Award(TM),(4) and in 2007, the pen was winner of a red dot product design award.(5) Last year, the NovoFine(R) Autocover(R) needle from Novo Nordisk was awarded a Medical Design Excellence Award.(6)

About NovoTwist(TM)

NovoTwist(TM) comes in 5 mm (32G Tip) and 8 mm (30G), and its novel bayonet fitting allows the user to twist the needle onto FlexPen(R). An audible and tactile 'click' confirms attachment of the needle. An integral glue tower minimises the risk of needle breakage, and short, thin needles ensure safe insulin deposition and reduce injection pain and bruising.(7-11)

For more information on NovoTwist(TM), please visit

About the Good Design Award(TM)

The Good Design Awards is a comprehensive programme for the evaluation and encouragement of design, organised by Japan Industrial Design Promotion Organization. The award's parent organisation is the Good Design Products Selection System (commonly known as the G-Mark system), established in 1957 by the then Ministry of International Trade and Industry (the current Ministry of Economy, Trade and Industry).

For more information on the G-Mark Awards, please visit

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 28,500 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit


    2.  Sommavilla et al. Expert Opin Pharmacother 2008; 9: 2223-32.
    3.  Lytzen & Ostfeldt. American Diabetes Association 69th Scientific
        Sessions; 2009; 1985-PO.
    5.  Data on file, Novo Nordisk A/S.
    7.  Hofman et al. Diabet Med 2007; 24: 1400-5.
    8.  Birkebaek et al. Diabet Care 2008; 31: e65.
    9.  Solvig et al. Diabetes 2001; 50 (Suppl. 2): A123.
    10. Iwanaga & Kamoi. Diabetes Technol Ther 2009; 11: 81-6.
    11. McKay et al. Diabetes Technol Ther 2009; 11: 195-201.

SOURCE Novo Nordisk

SOURCE Novo Nordisk
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
2. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
3. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
4. Dartmouth Medical School Faculty Member and Anesthesiologist Invents Revolutionary Catheter System Designed to Increase Rate of Successful IV Insertions by 75 Percent
5. SEI Defined Benefit Client Recognized With Leading Plan Design Award
6. Ethicon Endo-Surgery Wins Prestigious International Design Award for Innovative Development of HARMONIC FOCUS(TM)
7. Cortheras Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure
8. Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy
9. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
10. Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
(Date:11/24/2015)... Inc., an industry leader in LCD screen protection and glare-elimination technology, is providing a vital solution ... patient monitoring or electronic documentation system. Photo - ... ... ... A study in 2013 by the National Institutes of ...
(Date:11/24/2015)... 24, 2015 Abaxis, Inc. (NasdaqGS: ABAX ... consumables for the medical, research, and veterinary markets worldwide, ... Officer, will present at the 27 th Annual ... at 11:30 a.m. ET. The conference will be held ... New York City . Abaxis, Inc. ...
(Date:11/24/2015)... SCHAUMBURG, Ill. , Nov. 24, 2015  Wellness Center ... (PSI) November shipments of its flagship product, Psoria-Light® (PL 1000), to targeted ... , Houston, Minnesota , and North Carolina ... , Cleveland , Chicago , and ... --> --> Revenue for the earlier shipments reported on ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... Serenity Point Rehabilitation, a holistic treatment ... video interviews with some of the staff members at their recovery center. The videos ... as well as some of the things that make their recovery program so unique. ...
(Date:11/24/2015)... ... November 24, 2015 , ... Abington Hospital – Jefferson Health ... Quality® Bariatric Surgery Facility for treating individuals living with morbid or extreme obesity. ... available to its members to help them make informed decisions about their healthcare ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Specialty Health Fitness, ... have announced their endorsement of the Medical Fitness Network (MFN), a national health ... have the MFN as one of our endorsed organizations,” said ASH Fitness Vice ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... of patented products, announces Innovative Blending, a household invention that revolutionizes the vending ... Juice & Smoothie Bars market is worth $2 billion," says Scott Cooper, CEO ...
(Date:11/24/2015)... ... November 24, 2015 , ... Dehydration, defined as a loss ... to perspiration in the hot sun, and heat stroke and death will quickly follow. ... radio host Sharon Kleyne. Every cell, system and structure requires water to function properly. ...
Breaking Medicine News(10 mins):